Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Advanced Refractory Solid Tumors, Advanc...
Phase PHASE1, PHASE2
Enrollment 63
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory solid tumors to determine the RP2D. In the phase II portion, a total of 30 patients with advanced/metastatic TNBC will be enrolled.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Talazoparib — Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
  • Drug: Selinexor — Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)

Primary Outcomes

  • safety profile of combination of Talazoparib and Selinexor in advanced/ metastatic solid tumors using NCI CTCAE toxicity grading version 5.0. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-03-01
Completion: 2027-11
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 63 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National University Hospital, Singapore
Principal Investigators:
  • Soo Chin Lee (PRINCIPAL_INVESTIGATOR) - National University Hospital, Singapore
Contact Information
Study Contact:
Soo Chin Lee
6779 5555
soo_chin_lee@nuhs.edu.sg
Dr
National University Hospital
Interventions
  • Drug: Talazoparib — Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)
  • Drug: Selinexor — Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
Study Locations (1 sites)
National University Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: 1. All patients must sign an informed consent in accordance with local institutional guidelines. 2. All patient must not have received prior PARPi including talazoparib 3. All patients must not have prior therapy with selinexor. 4. Age ≥ 18 5. Estimated life expectancy of at least 12 weeks. 6. Has recovered from acute toxicities from prior anti-cancer therapies to grade 2 or lower. 7. a) Dose escalation phase: Patients with histologically or cytologically confirmed advanced or metastatic solid tumors who have radiological evidence of progressive disease on study entry that is deemed unlikely to benefit from further conventional therapy, or for which no standard therapy is available. b) Dose expansion phase: Patients with previously treated, advanced or metastatic histologically or cytologically confirmed triple negative breast cancers. Patients must have evidence of progressive disease on study entry after at least one line of anti-cancer therapy. Patients will be stratified into platinum-naïve (not having been treated with platinums-containing chemotherapy in the neoadjuvant, adjuvant or palliative setting), platinum sensitive (defined as having prior objective response or sustained disease control lasting ≥6 months to platinum-containing chemotherapy in the metastatic setting, or relapsed ≥6 months after completing neoadjuvant or adjuvant platinums-containing chemotherapy), and platinum resistant (defined as having progressive disease as the best response or disease control \<6 months to platinum-containing chemotherapy in the metastatic setting, or relapsed \<6 months after completing neoadjuvant or adjuvant platinums-containing chemotherapy). There is no upper limit on the number of prior treatments provided all inclusion/exclusion criteria are met. Hormone ablation therapy is considered an anti-cancer regimen. Radiation and surgery are not considered anti-cancer regimens. 8. Measurable disease by RECIST 1.1 criteria. 9. Eastern cooperative Oncology Group (ECOG) Performance Status of 0-1 10. Adequate bone marrow function and organ function within 2 weeks of study treatment 1. Adequate hematologic function defined as: * Absolute neutrophil (segmented and bands) count (ANC) ≥ 1.5 x 109/L * Platelets ≥ 125 x 109/L during dose escalation phase; platelets ≥ 100 x 109/L during dose expansion phase * Hemoglobin ≥ 9 x 109/L 2. Hepatic function: * Bilirubin ≤ 1.5 times the upper limit of normal (ULN) * ALT or AST ≤ 2.5 times ULN (or ≤ 5 times ULN with liver metastases) 3. Adequate renal function: * Calculated creatinine clearance of ≥ 60 mL/min, calculated using the formula of Cockroft and Gault: (140-Age) x Mass (kg)/(72 x creatinine mg/dL); multiply by 0.85 if female. 11. Able to swallow tablets/ pills. 12. Able to comply with study-related procedures. 13. Female patients of childbearing potential must have a negative serum pregnancy test at screening and agree to use highly effective methods of contraception throughout the study and for 7 months following the last dose of study treatment Exclusion Criteria: 1. Treatment within the last 30 days with any investigational drug. 2. Concurrent administration of any other tumour therapy, including cytotoxic chemotherapy, hormonal therapy, and immunotherapy 3. Major surgery within 28 days of study drug administration 4. Active infection that in the opinion of the investigator would compromise the patient's ability to tolerate therapy. 5. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator. 6. Pregnancy 7. Breast feeding 8. Poorly controlled diabetes mellitus 9. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment (for phase II only). 10. Symptomatic brain metastasis. 11. History of significant neurological or mental disorder, including seizures or dementia. 12. Unable to comply with study procedures 13. Current or anticipated use of strong P-gp inhibitors: amiodarone, carvedilol, clarithromycin, cobicistat, darunavir, dronedarone, erythromycin, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, telaprevir, tipranavir, valspodar, verapamil 14. Current or anticipated use of strong BCRP inhibitors: curcumin, cyclosporine A, eltrombopag, elacridar, fumitremorgin C, novobiocin, sulfasalazine
Conditions Breast Cancer Patients at High Risk of C...
Phase PHASE2
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT). It aims to investigate the efficacy and safety of hetrombopag in the secondary prophylaxis of CTIT. Breast cancer patients with histologically or cytologically confirmed disease were enrolled after signing the informed consent form and were randomly assigned in a 1:1:1 ratio to three Arms. Stratification factors for randomization included the number of prior antineoplastic treatment cycles (\>2 cycles vs. ≤2 cycles). Arm 1: No prophylactic use of hetrombopag Arm 2: Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle Arm 3: Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle; the dosage and administration schedule in the second chemotherapy cycle were identical to those in the first cycle; Treatment continued until patients completed the protocol-specified treatment and follow-up, experienced intolerable toxicity, withdrew informed consent, initiated alternative antitumor therapy, died, or met any other treatment discontinuation criteria specified in the protocol, whichever occurred first.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Continuous Hetrombopag for 2 Cycles — Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle
  • Drug: Cyclic 14-day Hetrombopag for 2 Cycles — Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle

Primary Outcomes

  • Incidence of grade ≥2 thrombocytopenia (PLT < 75×10⁹/L) (At the end of Cycle 2 (each cycle ≥21 days))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-16
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Jian Zhang
+8618017312991
syner2000@163.com
Jian Zhang
+8618017312991
syner2000@163.com
Fudan University Shanghai Cancer center
Interventions
  • Drug: Continuous Hetrombopag for 2 Cycles — Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 of the first chemotherapy cycle (C1D1) continuously until the end of the second chemotherapy cycle
  • Drug: Cyclic 14-day Hetrombopag for 2 Cycles — Hetrombopag at an initial dose of 7.5 mg once daily, administered from Day 1 (C1D1) to Day 14 (C1D14) of the first chemotherapy cycle
Study Locations (1 sites)
Fudan University Shanghai Cancer center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Patients with histopathologically confirmed breast cancer; 3. Receiving or expected to receive chemotherapy-based antitumor therapy with a cycle length of ≥21 days, and anticipated to receive ≥2 cycles of therapy; 4. ECOG performance status 0-2; 5. Platelet count meeting \*\*one\*\* of the following criteria: 1. Nadir platelet count \< 50×10⁹/L in the previous antitumor treatment cycle; 2. Nadir platelet count ≥ 50×10⁹/L but \< 75×10⁹/L in the previous antitumor treatment cycle, accompanied by \*\*high risk factors for bleeding\*\*\*; 6. Platelet count ≥ 100×10⁹/L at enrollment; 7. Patients with breast cancer plus other malignancies are allowed, provided that the treatment plan is primarily for breast cancer; 8. Adequate organ function: * Bone marrow: ANC ≥ 1.5×10⁹/L; hemoglobin ≥ 8 g/dL; * Hepatic and renal function: total bilirubin ≤ 1.5 × ULN; ALT, AST ≤ 2.5 × ULN (or ≤ 5 × ULN in the presence of liver metastasis); serum creatinine ≤ 1.5 × ULN or creatinine clearance \> 60 mL/min (Cockcroft-Gault formula); * Coagulation: activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤ 1.5 × ULN; 9. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose, not be breastfeeding, and agree to use effective contraception during the study and for 7 days after the last dose of study drug. Male subjects with female partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study and for 7 days after the last dose of study drug; sperm donation is prohibited during the study; 10. Life expectancy ≥ 3 months; 11. Voluntarily participate in the study, sign the informed consent form, have good compliance, and be willing to comply with follow-up procedures. * High risk factors for bleeding History of bleeding; prior treatment with platinum agents, gemcitabine, cytarabine, anthracyclines, PARP inhibitors (e.g., niraparib), etc.; combination of targeted agents and chemotherapeutic agents known to increase the risk of thrombocytopenia; history of radiotherapy or ongoing radiotherapy, especially to long bones and flat bones (e.g., pelvis, sternum). Exclusion Criteria: 1. Presence of hematological disorders, including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative neoplasms, multiple myeloma, and myelodysplastic syndromes; 2. Uncontrolled active infection; 3. History of arterial or venous thrombosis; 4. Patients with bleeding tendency, or evidence of inherited bleeding diathesis or coagulation disorders; 5. Pregnant or breastfeeding women, or female patients of childbearing potential not using effective contraception; 6. Participation in another clinical trial of thrombopoietic agents within 4 weeks prior to enrollment; 7. Presence of uncontrolled neurological or psychiatric disorders, poor compliance, or inability to cooperate and report treatment-related reactions; 8. Bone marrow involvement; 9. Administration of rhTPO or rhIL-11 within 7 days prior to enrollment; 10. Hypersensitivity to the study drug(s).
Conditions Advanced Solid Tumor, Adult, ERBB2 Alter...
Phase PHASE1
Enrollment 100
Locations 15 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CGT4255 — CGT4255 Daily Oral Administration

Primary Outcomes

  • Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Part A] (Approximately 12 months)
  • Overall Response Rate [Part B and Part C] (Approximately 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-12-30
Completion: 2028-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cogent Biosciences, Inc.
Contact Information
Study Contact:
Cogent Biosciences, Inc
617-945-5576
trialinfo@cogentbio.com
Interventions
  • Drug: CGT4255 — CGT4255 Daily Oral Administration
Study Locations (15 sites)
HonorHealth Research Institute, Scottsdale, Arizona 85258 United States
Mayo Scottsdale, Scottsdale, Arizona 85281 United States
Yale Cancer Center, New Haven, Connecticut 06510 United States
Mayo Jacksonville, Jacksonville, Florida 32209 United States
Northwestern University, Chicago, Illinois 60611 United States
LSU Health Sciences Center School of Medicine, New Orleans, Louisiana 70803 United States
START Midwest, Grand Rapids, Michigan 49546 United States
Mayo Rochester, Rochester, Minnesota 55905 United States
Washington University School of Medicine - Siteman Cancer Center, St Louis, Missouri 63110 United States
START NY Long Island, Lake Success, New York 11042 United States
Eligibility Criteria
Inclusion Criteria: 1. Have histologically confirmed diagnosis of: 1. Part A: Locally advanced, metastatic, and/or unresectable solid tumor with documented ERBB2-activating alteration or NRG1 gene fusion in blood and/or tumor or HER2 overexpression in tumor 2. Part B: Locally advanced, metastatic, and/or unresectable NSCLC with documented ERBB2 mutation in blood and/or tumor 3. Part C: Locally advanced, metastatic and/or unresectable breast cancer with documented ERBB2 mutation in blood and/or tumor or HER overexpression in tumor 2. Have measurable disease per RECIST v1.1. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 for Part A. For Parts B and C, ECOG Performance Status must be 0 to 2. 4. Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits. Exclusion Criteria: 1. Received small molecule chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug. 2. Major surgeries (eg, craniotomy and thoracotomy) within 4 weeks of the first dose of study drug. 3. Treatment with palliative focal radiotherapy (cranial or extracranial) (eg, stereotactic radiosurgery or intensity-modulated radiation therapy) ≤2 weeks before the first dose of study drug; treatment with whole-brain radiotherapy ≤4 weeks before the first dose of study drug. 4. Clinically significant cardiac disease. 5. Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of clinically significant laboratory abnormalities, before the first dose of study drug. 6. Restrictions on use of corticosteroid use to manage neurologic symptoms in different parts of the study.
Conditions Rectal Cancer Stage II, Rectal Cancer St...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test meal-timing as a novel and sustainable interventional approach during cancer treatment to improve therapeutic response and metabolic health in an understudied population. This clinical trial will enroll patients with rectal or breast cancer receiving neoadjuvant treatment at the Alaska Native Medical Center (ANMC), which is part of the Alaska Native Tribal Health Consortium (ANTHC). A promising strategy for improving the efficacy of anticancer treatments and reducing associated toxicities involves combining treatment with fasting regimens. In pre-clinical and clinical studies, various forms of fasting have been shown to induce tumor regression and improve long-term survival. According to the differential stress sensitization theory, fasting is thought to sensitize tumor cells to the cytotoxic effects of chemotherapy and radiation, while protecting healthy cells by increasing stress resistance. While healthy cells slow their growth and become more stress resistant in response to fasting, cancer cells cannot survive in nutrient-deficient environments; although the underlying mechanisms are not fully understood. However, extended water-only fasting can be challenging for patients and poses undue health risks. Intermittent fasting, and specifically time-restricted eating (TRE), may offer a viable alternative. TRE involves eating within a shorter window (e.g., 8 hours) and fasting for the remainder of the day but involves no other dietary restrictions. Because of its simplicity, TRE may be more sustainable than other fasting regimens. TRE also improves several cardio-metabolic endpoints, including insulin sensitivity, which may also be beneficial during anticancer treatments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Time-restricted eating — Participate in time-restricted eating plan
  • Other: Questionnaire Administration — Complete questionnaire
  • Procedure: Biospecimen Collection — Undergo collection of blood and stool
  • Behavioral: Health coaching — Receive nutrition counseling

Primary Outcomes

  • Pathological Complete Response (pCR) rate (At completion of neoadjuvant treatment (3-6 months))
  • Treatment-related toxicity (From enrollment until completion of neoadjuvant or adjuvant treatment (3-8 months))
  • Treatment Delivery (RDI and Completion) (From enrollment until completion of neoadjuvant or adjuvant treatment (3-8 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-23
Completion: 2029-08-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fred Hutchinson Cancer Center
Collaborators: National Cancer Institute (NCI), Alaska Native Tribal Health Consortium, Alaska Native Medical Center, Cedars-Sinai Medical Center
Principal Investigators:
  • Timothy Thomas, MD (PRINCIPAL_INVESTIGATOR) - Alaska Native Tribal Health Consortium (ANTHC)
  • Jane Figueiredo, PhD, M.Sc. (PRINCIPAL_INVESTIGATOR) - Cedars-Sinai Medical Center
Contact Information
Study Contact:
Timothy Thomas, MD
(907) 729-3095
tkthomas@anthc.org
Timothy Thomas, MD
(907) 729-3095
tkthomas@anthc.org
Alaska Native Medical Center (ANMC)
Timothy Thomas, MD
Alaska Native Medical Center (ANMC)
Interventions
  • Behavioral: Time-restricted eating — Participate in time-restricted eating plan
  • Other: Questionnaire Administration — Complete questionnaire
  • Procedure: Biospecimen Collection — Undergo collection of blood and stool
  • Behavioral: Health coaching — Receive nutrition counseling
Study Locations (1 sites)
Alaska Native Medical Center (ANMC), Anchorage, Alaska 99508 United States
Eligibility Criteria
Inclusion Criteria: * Male or female * Self-identify as Alaska Native or American Indian person and eligible for care at the ANMC * Age≥21 years * Histologically confirmed rectal cancer stage II, III, or IV (if curative) per AJCC criteria (neoadjuvant) * Histologically confirmed HER2+ or triple negative breast cancer stage I, II, or III, per AJCC criteria (neoadjuvant) * Histologically or cytologically confirmed solid tumor (adjuvant) * BMI≥18.5 kg/m2 * Plan to receive neoadjuvant or adjuvant therapy * Planned duration of neoadjuvant or systemic adjuvant therapy for \>3 months to allow sufficient time to assess impact of intervention * Must have capacity to give informed consent * Willing and able to adhere to the assessments, visit schedules, prohibitions, and restrictions * Has completed ≤ 4 weeks of neoadjuvant or adjuvant treatment prior to study enrollment * Score of \< 4 on U.S. Household Food Security Survey Module: Six-Item Short Form OR if score \>5, have clearance from dietitian Exclusion Criteria: * History of cytotoxic chemotherapy ≤12 months prior to rectal or breast cancer diagnosis (neoadjuvant) * Allergic reaction to any of the treatment agents * Any prior pelvic radiotherapy * Active second malignancy (exceptions: non-melanoma skin cancers or cervical carcinoma in situ adequately treated) requiring systemic therapy * History of GI perforation ≤12 months prior to enrollment * History of predisposing colonic or small bowel disorders with severe or rapidly worsening symptoms (not related to current cancer symptoms) * Receiving any parenteral nutrition or enteral (tube) feeding or using similar nutritional supplement during the study period * History of uncontrolled CHF defined as NYHA Class III or greater * Pre-existing grade ≥3 neuropathy * Currently participating in or has participated in a study of an investigational agent or investigational device ≤4 weeks of the first dose of treatment * Unstable psychiatric, sleep, or circadian conditions (common conditions such as sleep apnea and depression are acceptable as long as they are stabilized and not rapidly worsening) * Pregnant or breastfeeding * Currently perform overnight shift work \>1 day/week * Strictly adhering to a \<10-hour eating window on most days * Severe psychiatric, cognitive, or substance misuse disorders or social conditions that would interfere with adherence to study procedures.
Conditions Breast Cancer
Phase PHASE3
Enrollment 801
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The main objective of this trial is to investigate the efficacy and safety of hypofractionated radiotherapy of 3 or 4 weeks by comparing with conventional radiotherapy of 5 or 6 weeks using intensity-modulated radiation therapy (IMRT) in breast cancer patients with an indication for regional nodal irradiation (RNI) following mastectomy or breast conserving surgery. Patients will be randomized to hypofractionated radiotherapy or conventional radiotherapy delivered to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes). Eligible breast cancer patients will be followed for at least 5 years to evaluate the difference in 5-year locoregional recurrence, over survival, distant metastasis, toxicity and life quality between two groups.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Hypofractionated radiotherapy — 4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
  • Radiation: Conventional radiotherapy — 5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast

Primary Outcomes

  • Locoregional recurrence (LRR) (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2019-02-21
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 801 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ruijin Hospital
Collaborators: RenJi Hospital, Shanghai 10th People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Zhongshan Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Affiliated Hospital of Jiangnan University, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
Principal Investigators:
  • Jia-Yi Chen (STUDY_CHAIR) - Ruijin Hospital
Contact Information
Study Contact:
Jia-Yi Chen
+86-021-64370045
chenjiayi0188@aliyun.com
Jia-Yi Chen, M.D.
+86-021-64370045
chenjiayi0188@aliyun.com
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Jia-Yi Chen, M.D
+86-021-64370045
chenjiayi0188@aliyun.com
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Interventions
  • Radiation: Hypofractionated radiotherapy — 4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
  • Radiation: Conventional radiotherapy — 5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
Study Locations (1 sites)
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality 200025 China
Eligibility Criteria
Inclusion criteria : * Age 18-75 years old * unilateral histologically confirmed invasive breast carcinoma of pT1-3 * breast conservation surgery or mastectomy * Breast reconstruction is allowed * histologically confirmed positive axillary lymph nodes (positive sentinel lymph nodes without axillary dissection is allowed) * Life expectancy of \>5 years * A minimum negative surgical margin width of \>2mm * Karnofsky Performance Status ≥80 * Estrogen-receptor, Progesterone-receptor, human epidermal growth factor receptor-2 (HER-2) and Ki67 index can be performed on the primary breast tumor or axillary nodes. * Written informed consent Exclusion criteria: * Supraclavicular lymph nodes, positive ipsilateral internal mammary lymph nodes or residual axillary nodes that may be eligible for a boost dose. * Pregnant or lactating * Severe non-neoplastic medical comorbidities * Diagnosis of non-breast malignancy within 5 years preceding enrollment (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix). * Simultaneous contralateral breast cancer * Previous RT to thoracic and/or axillary, cervical region * Active collagen vascular disease * Evidence of distant metastatic disease and/or T4 disease Notes for exlusion criteria: 1. Patients with severe non-neoplastic medical comorbidities (e.g.,severe ischemic heart disease, severe arrhythmia or severe chronic obstructive pulmonary disease ) that would preclude radiation treatment will be excluded. 2. Simultaneous contralateral breast cancer includes histologically confirmed DCIS only.
Conditions Triple-Negative Breast Cancer (TNBC)
Phase PHASE3
Enrollment 504
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ESG401 — IV infusion on day 1,8, and 15 of each 28 day cycle
  • Drug: Investigator's Choice Chemotherapy — Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin

Primary Outcomes

  • Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) (Randomization up to approximately 28 months)
  • Overall Survival (OS) (Randomization up to approximately 41 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-09-04
Completion: 2028-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 504 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Qilu Pharmaceutical Co., Ltd.
Principal Investigators:
  • Fei Ma (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Xiaoyan Xing, PhD
+86 21 5855 6098
xingxiaoyan@escugen.com
Fei Ma, PhD
Fei Ma, PhD
8610-8778-8120
drmafei@126.com
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: ESG401 — IV infusion on day 1,8, and 15 of each 28 day cycle
  • Drug: Investigator's Choice Chemotherapy — Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin
Study Locations (1 sites)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Eligibility Criteria
Key Inclusion Criteria: 1. Males or females aged ≥ 18 years ; 2. Histologically and/or cytologically confirmed TNBC; 3. De novo metastatic or relapsed ≥ 6 months post completion of treatment with curative intent; 4. No prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease; 5. Participants whose tumours are PD-L1-negative, or Participants whose tumours are PD-L1-positive and have relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer, or comorbidities precluding PD-1/PD-L1 inhibitor therapy; 6. Eligible for the chemotherapy options listed as investigator's choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin) as assessed by the investigator; 7. At least one measurable lesion per RECIST v1.1; 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no worsening within 2 weeks prior to randomization; 9. A life expectancy of at least 12 weeks; 10. Adequate organ and bone marrow function. Key Exclusion Criteria: 1. Use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration. 2. Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1. 3. Prior topoisomerase I inhibitor therapy, including antibody-drug conjugate(ADC) therapy, or prior TROP2 targeted therapy. 4. New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months. 5. Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases. 6. Patients with Primary CNS malignancy, or patients with other malignancies within 3 years prior to the first dose. 7. Patients with uncontrollable systemic diseases. 8. Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea. 9. Subjects with clinically significant cardiovascular disease. 10. Human Immunodeficiency Virus (HIV) infection. 11. Active hepatitis B or hepatitis C. 12. Known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient. 13. Pregnant or lactating women.
Conditions Breast Cancer, Metastasis
Phase PHASE1, PHASE2
Enrollment 42
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib — 100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
  • Drug: Bicalutamide — 150 mg orally daily, day 1 to 28.

Primary Outcomes

  • The Dose-Limiting Toxicity (DLT) and Recommended Phase II Dose (RP2D) (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2021-09-20
Completion: 2028-06
Eligibility
Age: 18 Years – 90 Years
Sex: ALL
Volunteers: true
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Principal Investigators:
  • Amy Tiersten, MD (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Laura A Fiedler, MPH
(646) 957-1407
laura.fiedler@mssm.edu
Esther Kim, CRC
esther.kim@mssm.edu
Atul G Joshi, MS
212-824-7320
gargiatul.joshi@mssm.edu
Dubin breast Center
Interventions
  • Drug: Abemaciclib — 100 mg orally twice daily, day 1 to 28. If no toxicity in cycle 1 for the first 3 patients, increase dose to 150mg orally twice daily day 1-28 and enroll 3 patients. If excessive toxicity experienced at 100mg orally twice daily dose, decrease dose to 50mg orally twice daily day 1-28.
  • Drug: Bicalutamide — 150 mg orally daily, day 1 to 28.
Study Locations (3 sites)
Mount Sinai Beth Israel, New York, New York 10003 United States
Mount Sinai - West, New York, New York 10019 United States
Dubin breast Center, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses * If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study * Women aged at least 18 years * The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic HER2neu-negative breast cancer (including bone-only metastatic disease) o The patient must have had biopsy confirmation of a metastatic site (with appropriate ER/PR/HER2neu IHC staining) o The patient has measurable or evaluable disease as evidenced on pre-treatment baseline CT chest, abdomen, and pelvis with bone scan OR PET/CT * The patient has AR+ breast cancer (defined as \> or equal to 1% staining on immunohistochemistry of metastatic breast cancer specimen) * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks * If the patient has ER+ or PR+ (\>1% on IHC) metastatic breast cancer: o patient must have had 1 prior line of endocrine therapy in the metastatic setting * prior CDK4/6 inhibitor exposure allowed (abemaciclib. palbociclib, or ribociclib) * no more than 2 prior line of cytotoxic chemotherapy in the metastatic setting allowed * If the patient has ER-,PR-, HER2- metastatic breast cancer ("triple-negative"): o The patient may have had up to 4 prior lines of chemotherapy in the metastatic setting and at least 1 prior line of chemotherapy in the metastatic setting * Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy). * Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization. * Post-menopausal status or receiving ovarian ablation with a GnRH agonist such as goserelin or leuprolide. Postmenopausal status is defined by any one of the following criteria: * Prior bilateral oophorectomy. * Age ≥ 60 years. * Age \< 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, or ovarian suppression) and FSH, LH, and estradiol in the postmenopausal range per local normal. If the patient does not meet criteria for postmenopausal status but is receiving ovarian ablation therapy with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or leuprolide, the patient is eligible for the study, provided that the GnRH agonist is started at least 2 weeks prior to C1D1 of study therapy. \- Negative serum pregnancy test within 7 days prior to starting treatment • Women of child-bearing potential and men must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation, and for 3 weeks following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, as cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety evaluation. Note: Recommended methods of birth control are: The consistent use of an intrauterine device (IUD), Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam), Sexual abstinence (no sexual intercourse) or Sterilization. Men must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: * Has not undergone a hysterectomy or bilateral oophorectomy; or * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). Exclusion Criteria: * Treatment with any of the following: 1. Any investigational agents or study drugs from a previous clinical study within 28 days of the first dose of study treatment 2. Any other chemotherapy, immunotherapy or anticancer agents within 21 days of the first dose of study treatment 3. Any prior exposure to anti-androgen therapy (bicalutamide, abiraterone, and/or enzalutamide) * Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment * Spinal cord compression, leptomeningeal carcinomatosis, or brain metastases - unless asymptomatic, treated and stable and not requiring steroids for at least 2 weeks prior to start of study treatment * Concurrent use of endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane, oral contraceptive pills) * As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required. * Any of the following cardiac criteria: 1. Mean resting corrected QT interval (QTc) \> 470 msec obtained from 3 consecutive electrocardiograms (ECGs) 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block) 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, abnormalities in serum electrolytes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval 4. Personal history of syncope of cardiovascular etiology, ventricular arrhythmia (of pathologic origin including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. 5. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater 6. Uncontrolled hypotension - Systolic BP \<90mmHg and/or diastolic BP \<50mmHg 7. Left ventricular ejection fraction (LVEF) below lower limit of normal for site * Prior history of DVT/PE or embolic stroke, unless currently on therapeutic anticoagulation * Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: 1. Absolute neutrophil count \< 1.5 x 109/L 2. Platelet count \< 100 x 109/L 3. Hemoglobin \< 8 g/L (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.) 4. Alanine aminotransferase \> 3 times the upper limit of normal (ULN) 5. Aspartate aminotransferase \> 3 times ULN 6. Total bilirubin \> 1.5 times ULN (patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted) 7. Creatinine \>1.5 times ULN concurrent with creatinine clearance \< 50 ml/min (measured or calculated by Cockcroft and Gault equation); confirmati
Conditions Breast Cancer, Invasive Breast Cancer
Phase PHASE1
Enrollment 10
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether it is practical (feasible) to use a new type of imaging scan called 68Ga-FAPI PET/MRI (positron emission tomography/magnetic resonance imaging) to evaluate how well breast cancer responds to neoadjuvant chemotherapy.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 68Ga-FAPI-PET/MRI — 68Ga-FAPI-PET/MRI is conducted 3 times in every participant.

Primary Outcomes

  • Number of participants able to complete all 3 planned scans (Up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-10-20
Completion: 2028-10-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Somali Gavane, MD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Somali Gavane, MD
212-639-2403
GavaneS@mskcc.org
Roberto Valentin, MD
ValentR2@mskcc.org
Somali Gavane, MD
212-639-2403
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Interventions
  • Diagnostic Test: 68Ga-FAPI-PET/MRI — 68Ga-FAPI-PET/MRI is conducted 3 times in every participant.
Study Locations (8 sites)
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey 07748 United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack, New York 11725 United States
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activity), Commack, New York 11725 United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States
Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York 11553 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * ECOG Performance Status of ≤ 2 * Ability to review and signed informed consent * Histologically confirmed, newly diagnosed invasive breast cancer * Lymph node metastases (either histologically confirmed or radiographic evidence of lymph node metastases). * Planned to undergo SOC NAC prior to surgical resection as outlined in section 4.1 Exclusion Criteria: * Pregnancy or lactation. * Patients who cannot undergo PET/MRI scanning because of: * devices or implants that are not MRI safe * hypersensitivity or known allergy to gadolinium-based contrast agents * physical fitness not allowing scanning in prone for 30 minutes * weight limits (450 lb. weight limit) * Severe kidney disfunction (estimated GFR \< 30 ml/min/1.73 m2) (CKD-EPI (2021)) * Imaging features suspicious for concomitant in-situ cancer (LCIS/DCIS), such as nonbiopsied groups of microcalcifications * Distant metastases (contraindication for NAC)
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE2
Enrollment 86
Locations 30 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving nab-paclitaxel, durvalumab, and tremelimumab with or without neoantigen vaccine will work better in treating patients with triple negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Procedure: Biopsy Procedure — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood and urine sample collection
  • Drug: Carboplatin — Given IV
  • Procedure: Computed Tomography — Undergo CT scan
  • Biological: Durvalumab — Given IV
  • Drug: Gemcitabine Hydrochloride — Given IV
  • Procedure: Magnetic Resonance Imaging — Undergo MRI
  • Drug: Nab-paclitaxel — Given IV

Primary Outcomes

  • Progression-free survival (PFS) (From initiation of Part B to progression or death, assessed at 6 and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-04-13
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • William E Gillanders (PRINCIPAL_INVESTIGATOR) - Yale University Cancer Center LAO
Contact Information
Study Contact:
Site Public Contact
720-848-0650
UCHealth University of Colorado Hospital
Jennifer R. Diamond
UCHealth University of Colorado Hospital
Site Public Contact
954-461-2180
UM Sylvester Comprehensive Cancer Center at Aventura
Interventions
  • Procedure: Biopsy Procedure — Undergo tumor biopsy
  • Procedure: Biospecimen Collection — Undergo blood and urine sample collection
  • Drug: Carboplatin — Given IV
  • Procedure: Computed Tomography — Undergo CT scan
  • Biological: Durvalumab — Given IV
Study Locations (30 sites)
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States
University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States
UCHealth University of Colorado Hospital, Aurora, Colorado 80045 United States
Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut 06105 United States
Yale University, New Haven, Connecticut 06520 United States
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida 33180 United States
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida 33146 United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida 33442 United States
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida 33136 United States
UM Sylvester Comprehensive Cancer Center at Kendall, Miami, Florida 33176 United States
Eligibility Criteria
Inclusion Criteria: * Patients must have a histologically confirmed diagnosis of metastatic invasive triple negative breast cancer. Patients with clinical and/or radiologic suspicion of metastatic TNBC can be consented prior to this confirmation. * Estrogen receptor (ER) and progesterone receptor (PR) less than Allred score of 3 OR less than 1% positive staining cells in the invasive component of the tumor. * HER2 negative by fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) staining 0 or 1+. * PD-L1 negative by a Clinical Laboratory Improvement Act (CLIA) approved laboratory using compatible assays appropriate for treatment decisions. * Patients may have measurable or evaluable disease. * Patients must be willing to undergo biopsy and have accessible lesions for a new biopsy, or they must have sufficient tissue available from a biopsy performed for standard of care (specifications below). If patient does not have enough archived tissue available, a new biopsy is required. A tumor specimen obtained from relapsed primary, metastatic, or locally advanced sites of disease (if applicable) must be submitted. Acceptable samples include core needle biopsies for deep tumor tissue (minimum 4 cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. Formalin-fixed, paraffin-embedded (FFPE) tumor specimens in paraffin blocks are preferred; FFPE tumor tissue sections on slides may be provided if sufficient material (15 x 10μ, unstained) is available. Fine-needle aspiration, brushing, cell pellet from pleural effusion, bone metastases, and lavage samples are not acceptable. * No prior therapy for metastatic TNBC. Patients who have received taxane-based adjuvant therapy are required to have a disease-free interval of at least 12 months after completion of taxane therapy. * Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of durvalumab (MEDI4736) and tremelimumab in combination with neoantigen vaccine in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 60%). * Body weight \> 30 kg. * Must have a life expectancy of at least 12 weeks. * Absolute neutrophil count \>= 1,500/mcL. * Platelets \>= 100,000/mcL. * Hemoglobin \>= 9.0 g/dL. * Serum bilirubin =\< 1.5 x institutional upper limit of normal. * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) =\< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =\< 5 x institutional upper limit of normal. * Calculated creatinine clearance \> 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance. * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). * Women \>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). * The effects of durvalumab (MEDI4736) and tremelimumab and neoantigen vaccine on the developing human fetus are unknown. For this reason and because these agents may be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 180 days after completion of durvalumab (MEDI4736) and tremelimumab. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. * Human immunodeficiency virus (HIV)-positive patients are eligible provided they have a negative viral load, CD4 count \> 250, and are on a stable antiretroviral regimen. * Ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity who have a close caregiver or legal guardian are also eligible with the consent of the caregiver/guardian. Exclusion Criteria: * Patients who are not considered to be candidates for carboplatin + gemcitabine for first line therapy of their metastatic triple negative breast cancer are not eligible. * Patients who have had chemotherapy, radiotherapy (to more than 30% of the bone marrow), or biologic therapy within 30 days (42 days for nitrosoureas or mitomycin C) prior to entering the study. * Patients who have received prior immunotherapy for metastatic disease. * Patients who have not recovered from grade \>= 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. * Patients with grade \>= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician. * Patients with grade \>= 2 endocrinological adverse events (AEs), (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus), must have been on a stable dose of supplemental therapy for at least 2 weeks before screening to be eligible for this study, and the endocrinological AE must be stable in the opinion of the treating physician. * Patients who are receiving any other investigational agents or who have received an investigational agent within the last 30 days. * Receipt of live attenuated vaccination within 6 months prior to study entry or within 30 days of receiving durvalumab (MEDI4736) and tremelimumab. * Note: Patients, if enrolled, should not receive live vaccine whilst receiving study treatment and up to 30 days after the last dose of study treatment. * Major surgical procedure within 28 days prior to the first dose of durvalumab (MEDI4736) and tremelimumab. Local surgery of isolated lesions for palliative intent is acceptable. * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab (MEDI4736) or tremelimumab. The following are exceptions to this criterion: * Intranasal, inhaled, topical steroids or local steroid injections (e.g. intra-articular injection) * Systemic corticosteroids at physiological doses which are not to exceed 10 mg/day of prednisone or an equivalent corticosteroid * Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication) * Steroids for symptoms from brain metastases as defined. * Spinal cord compression or active brain metastases and/or carcinomatous meningitis. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to registration are eligible if they meet all of the following criteria: * Residual neurological symptoms have resolved to grade =\< 2 * On stable doses of dexamethasone, if applicable and if acceptab
Conditions Resectable HER2-positive Breast Cancer
Phase PHASE3
Enrollment 1800
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: KN026 — In accordance with the protocol
  • Drug: HB1801 — In accordance with the protocol
  • Drug: Trastuzumab — Intravenous infusion
  • Drug: Pertuzumab — Intravenous infusion
  • Drug: Docetaxel — Intravenous infusion
  • Drug: Epirubicin — Intravenous infusion
  • Drug: Doxorubicin — Intravenous infusion
  • Drug: Cyclophosphamide — Intravenous infusion

Primary Outcomes

  • iDFS (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-03-06
Completion: 2035-08-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai JMT-Bio Inc.
Contact Information
Study Contact:
Clinical Trials Information Group officer
0311-69085587
ctr-contact@cspc.cn
Clinical Trials Information Group Clinical Trials Information Group
021-64175590-88503
JJYIN555@163.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: KN026 — In accordance with the protocol
  • Drug: HB1801 — In accordance with the protocol
  • Drug: Trastuzumab — Intravenous infusion
  • Drug: Pertuzumab — Intravenous infusion
  • Drug: Docetaxel — Intravenous infusion
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 201318 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily participate and sign the informed consent form. 2. Age ≥ 18 years. 3. ECOG performance status score of 0 or 1. 4. Histologically or cytologically confirmed invasive breast cancer. 5. Must have undergone prior radical mastectomy or breast-conserving surgery for breast cancer. 6. Pathologically confirmed positive regional lymph nodes. 7. Tumor tissue confirmed as HER2-positive by the local laboratory. 8. Adequate organ and bone marrow function: 1. Absolute neutrophil count ≥ 1.5 × 10⁹/L 2. Platelet count ≥ 100 × 10⁹/L 3. Hemoglobin ≥ 90 g/L 4. Liver function: Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for participants with Gilbert's syndrome); ALT and AST ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN 5. Coagulation function: INR ≤ 1.5 × ULN and aPTT ≤ 1.5 × ULN 6. Renal function: Creatinine clearance ≥ 50 mL/min 7. LVEF ≥ 55% 9. Female participants of childbearing potential must have a negative blood pregnancy test result within 7 days prior to randomization, and agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment. Male participants with female partners of childbearing potential must agree to use reliable and effective contraception during the study treatment period and for 7 months after the last dose of study treatment. Exclusion Criteria: 1. History of any prior ipsilateral and/or contralateral invasive breast cancer. 2. History of other malignancy within 5 years prior to randomization, except for the breast cancer under study and locally curable malignancies treated with curative intent. 3. Prior systemic chemotherapy, endocrine therapy, anti-HER2 targeted therapy, or local radiotherapy for breast cancer. 4. Use of strong CYP3A4 inhibitors within 14 days prior to randomization or planned use during the combination chemotherapy period. 5. Known contraindication to any study drug or history of hypersensitivity to any component or known excipient of the study drugs. 6. Significant cardiovascular disease history, including: prior coronary artery bypass graft or coronary stenting; myocardial infarction or cerebrovascular accident within 6 months prior to randomization; history of congestive heart failure/systolic dysfunction (LVEF \< 50%) or unstable angina; history of clinically significant prolonged QT interval or QTcF (Fridericia) \> 450 ms at screening; uncontrolled severe hypertension (systolic BP \> 180 mmHg and/or diastolic BP \> 100 mmHg); high-risk arrhythmias \[e.g., atrial tachycardia with resting heart rate ≥ 100 bpm, significant ventricular arrhythmia (ventricular tachycardia), or high-grade atrioventricular block (Mobitz type II second-degree or third-degree AV block)\]. 7. Severe chronic or active infection requiring intravenous anti-infective therapy within 14 days prior to randomization. 8. Participation in another interventional clinical trial within 4 weeks prior to randomization. 9. Pregnant or lactating women. 10. Any other condition that may interfere with the participant's ability to comply with study procedures, may not be in the participant's best interest to participate, or may affect study results (e.g., history of neurological or psychiatric disorders, alcohol or drug abuse, or any other clinically significant disease or condition).
Conditions Breast Cancer
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The purpose the BRENAR pilot study is to assess acute post-surgical complications following mastectomy and immediate breast reconstruction after neoadjuvant radiotherapy (NART). The investigators hypothesize that NART will avoid the negative effects of postmastectomy radiotherapy (PMRT) on the capsule of an implant, or on the skin and underlying tissue of an autologous flap, and would therefore lead to better cosmetic results, better quality of life and less complications compared to PMRT. If this hypothesis is confirmed, NART would allow more patients to undergo an immediate reconstruction resulting in superior cosmetic results and quality of life. Furthermore, the use of RT in a neoadjuvant setting could potentially result in a shorter overall loco-regional treatment time from diagnosis to receiving the last locoregional treatment. However, this pilot study will mainly assess whether or not the post-surgical complications of breast reconstruction with NART are acceptable. Further study to investigate long term quality of life and oncologic follow-up results will be conducted after this pilot study, if complication rates are acceptable.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Neoadjuvant radiotherapy — The study examines the delivery NART. In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied. A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap.

Primary Outcomes

  • Acute post-surgical complication rate at 3 months following mastectomy and immediate breast reconstruction after NART in the treatment of breast cancer. (3 months following mastectomy and immediate breast reconstruction (latest intervention, being either autologous recosntruction or silicone implant))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-01
Completion: 2026-12-04
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UMC Utrecht
Collaborators: Alexander Monro Hospital, Bilthoven, Amsterdam UMC, Cancer Center Amsterdam grant for innovative research
Contact Information
Study Contact:
Wies Maarse, PhD, MD
+31626598153
w.maarse@umcutrecht.nl
Wiesje W Maarse
0626598153
w.maarse@umcutrecht.nl
Maarse Wiesje
Interventions
  • Radiation: Neoadjuvant radiotherapy — The study examines the delivery NART. In case of neoadjuvant chemotherapy, RT will start 6-8 weeks after the last course of chemotherapy. A dose of 15 x 2.67 Gy 5 fractions per week, or a biologically equivalent dose will be applied. A mastectomy and a direct breast reconstruction will be performed, approximately 2-6 weeks after latest radiotherapy treatment. Breast reconstruction can be separated in the types of reconstruction, either reconstruction with a silicone implant or with only autologous tissue, of which the most common flap used is the Deep Inferior Epigastric Perforator (DIEP) flap.
Study Locations (1 sites)
Maarse Wiesje, Bilthoven, Utrecht 3722 AG Netherlands
Eligibility Criteria
Inclusion Criteria: * In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Females at least 18 years of age. * WHO performance scale ≤2 * Adequate communication and understanding skills of the Dutch language * Able to understand and sign Dutch written informed consent * Indication for mastectomy and a known indication for (adjuvant) radiotherapy of at least the chestwall. To obtain information on the indication for RT, before the mastectomy is performed, it may be necessary to perform a separate SNP and/or targeted axillary dissection prior to inclusion, i.e. * Stage III (cT3N1, cT0-2N2-3) or cN1 with more than 3 suspicious nodes at initial diagnosis * A positive SN/TAD\* pre- breast surgery in case of: * cT1-2N0 and less than 3 RF\*\* at initial diagnosis and cCR on imaging\*\*\* * cT3N0 and no risk factor at initial diagnosis * If the indication for radiotherapy is not yet clear, and is only indicated when there is a pathological lymph node present, a sentinel node procedure or targeted axillary dissection (TAD) will be performed first to check for the lymph node status. A sentinel node procedure (SNP) will be performed under general anesthesia in order to explore regional lymph nodes. For cT1-3N0 patients, it is known that about 25% has a positive axillary node after neoadjuvant chemotherapy (50);for patients with cT1-3N+ breast cancer, about 55-70% still have positive nodes after neoadjuvant chemotherapy, which is dependent of receptor status 29,30,31,32,33. Consequently, we may have to ask for informed consent 2-4 times more patients than we would need for this pilot study. * risk factors are: angio invasion, Grade III, Age ≤ 40 yrs, triple negative \*\*\* In patients with cT1-2N0 with at least 3 RF a tumour biopsy can be considered prior to surgery in case of neoadjuvant chemotherapy, since in case of no pCR the indication for RT is already set, and an SN or TAD prior to breast surgery is not required. Exclusion Criteria: * study: * Legal incapacity * Not able to understand and sign Dutch written informed consent * Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla * Collagen synthesis disease * MRI absolute contraindications as defined by the Radiology Department * Age \< 18 year * Pregnant or lactating. * Smoking * BMI \> 35 kg/m2 * cT4 tumour (and skin sparing mastectomy not possible) * If NAC in cT1-2N0 and 3 RF: in triple negative or Her2 positive (with concern for under treatment of adjuvant therapy) and no tumor cells in preoperative biopsy\* * NB: If neoadjuvant chemotherapy is given, and if the indication for adjuvant systemic treatment is dependent on the presence or absence of a pathological complete response pCR (such as in patients with a triple negative or Her2 positive tumour), centres can choose A) to exclude these patients, or B) only to include these patients when a non-pCR is proven via a biopsy prior to the start of the RT. Earlier studies in partial breast RT showed that pCR rate of NART only, followed by surgery \< 6-8 weeks is very low in the general breast cancer population (17 of the 110), whilst it seems to be higher in patients with triple negative (6/8) and Her2 positive (1/1) (personal communication Sophie Bosma, trial on Preoperative Accelerated Partial Breast Irradiation, PAPBI trial 34.
Conditions Non Small Cell Lung Cancer, Esophageal C...
Phase PHASE1
Enrollment 540
Locations 37 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-03
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-B01D1 — BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen

Primary Outcomes

  • Participants with Dose-limiting toxicities (One year)
  • Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs), (One year)
  • Participants with abnormal physical examination findings (One year)
  • Participants with ability to care for themselves, daily activity, and physical activity (One year)
  • Participants with abnormal ECG reading (One year)
  • Participants with abnormal lab results (One year)
  • To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-08-08
Completion: 2030-07-22
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SystImmune Inc.
Principal Investigators:
  • Jimmy Zhao, MD, PhD (STUDY_DIRECTOR) - SystImmune Inc.
Contact Information
Study Contact:
Tara Barrineau
425-453-6841
tara.barrineau@systimmune.com
Tara Barrineau
tara.barrineau@systimmune.com
Afshin Gabayan
eligabayan@bhcancercenter.com
Beverly Hills Cancer Center
Interventions
  • Drug: BL-B01D1 — BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
Study Locations (37 sites)
Beverly Hills Cancer Center, Beverly Hills, California 90211 United States
City of Hope Cancer Center, Duarte, California 91010 United States
University of California Irvine Medical Center, Orange, California 92868 United States
UCLA Santa Monica, Santa Monica, California 90404 United States
University of Colorado Cancer Center, Aurora, Colorado 80045 United States
Yale University, Yale Cancer Center, New Haven, Connecticut 06520 United States
Georgetown University Medical Center, Washington D.C., District of Columbia 20007 United States
Sylvester Comprehensive Cancer Center, Miami, Florida 33125 United States
Sara Cannon Research Institute Lake Nona, Orlando, Florida 32827 United States
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida 34952 United States
Eligibility Criteria
Inclusion criteria: 1. Signed the informed consent voluntarily and agreed to follow the program requirements 2. Either sex 3. Age: ≥18 years 4. Has a life expectancy of ≥3 months 5. Has histologically documented, incurable, locally advanced or metastatic epithelial origin malignant cancer, priority to include the following tumor types: NSCLC, HER2 - breast cancer, esophageal cancer, SCLC, NPC, and HNSCC. Has documented locally advanced or metastatic HER2 negative (by immunohistochemistry \[IHC\], score of 0 or 1) Hormone Receptor (HR) positive (HER2-, HR+) OR HER2 negative (IHC score of 0 to 2) HR negative breast cancer (HER2-, HR-) as per ASCO CAP criteria (ASCO CAP 2023; Wolff et al. 2023), not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease, must have received 1 prior line of chemotherapy for advanced disease and, when applicable and if approved in that region, a PD-1/PD-L1 inhibitor, either given concurrently or sequentially. When appropriate, must have progression on at least 1 prior line of hormonal therapy with or without a targeted therapy (such as CDK4/6, mTOR, or PI3-K inhibitors) administered for treatment of metastatic disease. In Dose Escalation and Dose finding portions of the study, for triple-negative breast cancer (TNBC, HER2-/HR-) participants must have received PARP inhibitors if a BRCA mutation is present and sacituzumab govitecan as second line treatment. Participants who are HER2 low must have received trastuzumab deruxtecan. 6. Agree to provide archived tumor samples (tissue block or slides) from primary or metastatic sites within 2 years. In the event that no archival tissue is available a fresh tissue biopsy is highly encouraged but not mandatory. 7. Has at least one measurable lesion based on RECIST V1.1 (with the exception of Prostate adenocarcinoma cohort, where subjects with bone metastasis are allowed) 8. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1 9. Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevated ALP, hyperuricemia, elevated serum or plasma amylase/lipase, and elevated blood glucose; except for toxicity that the investigator determined to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.) 10. Has no serious cardiac dysfunction, left ventricular ejection fraction ≥50% 11. Has adequate organ function before registration, defined as: a) Marrow Function: Absolute neutrophil count (ANC) ≥1.2×109 /L, Platelet count ≥100×109 /L, Hemoglobin (Hb) ≥90 g/L b) Hepatic function: Total bilirubin(TBIL≤1.5 ULN, AST and ALT without liver metastasis ≤2.5 ULN, AST and ALT with liver metastasis ≤5.0 ULN c) Renal function: Creatinine clearance ≥50 mL/min (According to the Cockcroft and Gault equation) 12. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5 ULN 13. Urinary protein ≤2+ or ≤1000mg/24 hours 14. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months for females and 4 months for males after the last dose of study treatment. An additional contraceptive method, such as a barrier method like a condom is required. 15. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female subjects are considered WOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \>45 years old in the absence of other biological or physiological causes. In addition, females \<55 years old must have a serum follicle stimulating hormone (fsh) level \> 40 mIU/mL to confirm menopause. 16. For subjects with NSCLC (EGFR mutation): a) Evidence of documented EGFR TKI-sensitizing deletion mutation in EGFR Exon 19 (ex19del) or leucin-arginine substitution point mutation in EGFR Exon 21 (ex21L858R), the serine-isoleucine mutation in EGFR Exon 20 (ex20S768I), the leucine-glutamine substitution mutation in Exon 21 (ex21L861Q), or the glycine substitution (with alanine, cysteine, or serine) mutation in Exon 18 (ex18G719X) at or after the time of disease diagnosis and prior to initiation of treatment. 17. For Triple-Negative Breast Cancer (TNBC, HER2-/HR-): a) Histologically or cytologically confirmed and documented locally advanced, recurrent inoperable or metastatic TNBC 18. For Esophageal adenocarcinoma a) Has locally advanced or metastatic adenocarcinoma cell carcinoma of the esophagus or esophagogastric junction cancers, not amenable to curative surgery or radiation with documentation of radiological disease progression after one line of fluoropyrimidine and/or platinum-based chemotherapy treatment regimen for locally advanced or metastatic disease. NOTE: Prior therapies such as trastuzumab, zolbetuximab, or IOs are allowed in the study. 19. For Prostate adenocarcinoma a) Subject has metastatic castration-resistant prostate cancer (mCRPC) after progression on/after an androgen receptor pathway inhibitors (ARPI) treatment, such as abiraterone, enzalutamide, apalutamide and darolutamide. Note: No prior chemotherapy including docetaxel is allowed Prior treatment with lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is allowed. Enrollment will be capped for lutetium Lu 177 vipivotide tetraxetan-naive participants at approximately 20 or participants with prior lutetium Lu 177 vipivotide tetraxetan treatment at approximately 20. 20. For NSCLC (EGFR wild type) with squamous histology 1. Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease with predominantly squamous cell histology 2. Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1). 3. Progressed or intolerant to one line of platinum-based chemotherapy with α-PD-1/L1 monoclonal antibody given either concurrently or sequentially. 21. For NSCLC (EGFR wild type) with adenocarcinoma histology 1. Has documented locally advanced or metastatic NSCLC, not amenable to curative surgery or radiation with documentation of radiological disease progression while on/after receiving most recent treatment regimen for locally advanced or metastatic disease with predominantly adenocarcinoma histology 2. Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1). Progressed or intolerant to one line of platinum-based chemotherapy with α-PD-1/L1 monoclonal antibody given either concurrently or sequentially. 22. Ovarian adenocarcinoma a) Has histologic documentation of epithelial ovarian, primary peritoneal, or fallopian tube cancer that has progressed or relapsed on or after a previous platinum-containing chemotherapy with or without a PARP inhibitor. Note: participants with platinum-sensitive or platinum resistant recurrent ovarian cancer (PSR) are eligible. However, enrollment will be capped for platinum-sensitive or platinum resistant participants at approximately 20 each. Prior bevacizumab treatment is allowed. 23. Endometrial carcinoma a) Has relapsed, advanced and/or metastatic endometrial ca